Previous Close | 6.39 |
Open | 6.38 |
Bid | 6.20 x 800 |
Ask | 6.50 x 900 |
Day's Range | 6.33 - 6.63 |
52 Week Range | 1.98 - 6.95 |
Volume | |
Avg. Volume | 234,665 |
Market Cap | 175.034M |
Beta (5Y Monthly) | 2.04 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.46 |
Earnings Date | Mar 06, 2023 - Mar 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Neuronetics Inc (NASDAQ: STIM) and Greenbrook TMS Inc (NASDAQ: GBNH) announced an expanded commercial partnership through year-end 2028. Under the partnership agreement, Neuronetics will be the exclusive supplier of transcranial magnetic stimulation (TMS) equipment to Greenbrook. Over time, Neuronetics' NeuroStar devices will replace competitive TMS devices at Greenbrook locations. The agreement also has minimum purchase commitments, and all treatment session purchases will convert to a "per-cli
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders (“Neuronetics”), and Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH), a leading provider of transcranial magnetic stimulation (“TMS”) therapy (“Greenbrook”), today announced an expanded commercial partnership thro
MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the award was approved by Neuronetics’ Compensation Committee and made as a material induce